Therefore, as a single agent inhibiting TGF-β signaling and Bcl-2 expression, naftopidil could be an effective inhibitor of the TGF-β/acetylated KLF5 signaling axis for overcoming DTX resistance in prostate cancer. Here, TGFB1 is linked to Familial prostate cancer.